StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical ...

The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Analysts initiated coverage on Septerna, Inc. with Overweight ratings and price targets of $50 and $38. SEPN's innovative ...

Moreover, the lead product, SEP-786, shows promise as a convenient oral alternative to existing injectable treatments for hypoparathyroidism. The preclinical results have been impressive, showing ...

Furthermore, Septerna’s strategic focus on validated targets in large market indications, such as their lead candidate SEP-786 for hypoparathyroidism, positions them well for future success. The ...

MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH ...

Currently 4.4 million people in the UK who live with diabetes are at a higher risk of developing eye diseases and vision loss ...

Michele Rayes used to take 64 pills a day to man­age her hy­poparathy­roidism, a rare en­docrine dis­or­der that im­pairs cal­ci­um lev­els, damp­ens dai­ly qual­i­ty of … ...

Entera's proprietary N-Tab™ platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and ...

Entera's proprietary N-Tab platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and confidential hypoparathyroidism tablet program. Finally, we are humbled by key ...